Anuh Pharma Ltd Falls to 52-Week Low of Rs.68 Amidst Continued Downtrend

Stock Performance and Market Context

On 27 Jan 2026, Anuh Pharma Ltd (Stock ID: 905552), operating in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low price of Rs.68. This represents a notable drop from its 52-week high of Rs.115, underscoring a year-long decline of 26.28%. In comparison, the Sensex has delivered a positive return of 8.41% over the same period, highlighting the stock’s relative underperformance.

Today’s trading session saw the stock fall by 0.32%, underperforming its sector by 0.57%. The stock has declined for two consecutive days, losing 0.55% in returns during this period. Furthermore, Anuh Pharma is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating persistent bearish momentum.

Meanwhile, the broader market showed resilience with the Sensex recovering from an initial drop of 100.91 points to close 264.39 points higher at 81,701.18, a 0.2% gain. Mega-cap stocks led the market rally, while some indices such as NIFTY MEDIA and NIFTY REALTY also hit new 52-week lows today.

Financial Metrics and Profitability Trends

Over the last five years, Anuh Pharma’s net sales have grown at a modest annual rate of 13.69%, while operating profit has expanded at a slower pace of 7.18%. These growth rates have not translated into stronger profitability, as reflected in recent quarterly results.

The company reported a Profit Before Tax (PBT) of Rs.8.94 crores in the latest quarter, a decline of 29.3% compared to the average of the previous four quarters. Similarly, Profit After Tax (PAT) for the latest six months stood at Rs.15.91 crores, down by 35.19%. Return on Capital Employed (ROCE) for the half-year period was recorded at 15.90%, one of the lowest levels in recent years.

Despite these challenges, Anuh Pharma maintains a low average debt-to-equity ratio of zero, indicating a debt-free balance sheet. The company’s Return on Equity (ROE) is 11.8%, and it trades at a Price to Book Value of 2.2, suggesting valuation metrics that are broadly in line with its peers’ historical averages.

Market Position and Institutional Holding

Despite its size, Anuh Pharma has negligible domestic mutual fund ownership, with funds holding 0% of the company’s shares. Given that domestic mutual funds typically conduct thorough research and maintain stakes in companies they find favourable, this absence may reflect a cautious stance on the stock’s current valuation or business outlook.

The stock’s Mojo Score stands at 28.0, with a Mojo Grade of Strong Sell as of 8 Jan 2026, downgraded from a Sell rating. The Market Cap Grade is 4, indicating a mid-tier market capitalisation relative to other listed companies.

Over the past year, the company’s profits have declined by 34.4%, further contributing to the stock’s subdued performance. This contrasts with the broader BSE500 index, which has generated returns of 8.43% in the same timeframe.

Technical Indicators and Trading Trends

The stock’s position below all major moving averages signals a persistent bearish trend. The 5-day, 20-day, 50-day, 100-day, and 200-day moving averages all lie above the current price of Rs.68, indicating that short-term and long-term momentum remain weak.

In contrast, the Sensex is trading below its 50-day moving average but above its 200-day moving average, suggesting a more mixed but generally stable market environment. The divergence between Anuh Pharma’s technical indicators and broader market trends highlights the stock’s relative weakness.

While the company’s low debt levels and fair valuation metrics provide some stability, the declining profitability and lack of institutional support continue to weigh on the stock’s performance.

Summary of Key Financial and Market Metrics

To summarise, Anuh Pharma Ltd’s stock has reached a 52-week low of Rs.68, reflecting a 26.28% decline over the past year. The company’s financial results show a contraction in profits, with PBT down 29.3% and PAT down 35.19% in recent periods. The ROCE at 15.90% and ROE at 11.8% indicate moderate returns on capital and equity, while the zero debt-to-equity ratio points to a conservative capital structure.

The stock’s Mojo Grade of Strong Sell and low Mojo Score of 28.0 further underline the challenges faced by the company in the current market environment. Trading below all major moving averages and lacking significant mutual fund ownership, Anuh Pharma remains under pressure amid a broader market that is showing signs of resilience.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →